Incorporating common biomarkers into the clinical management of heart failure

被引：4
作者：
Halkar M. [1 ]
Tang W.H.W. [2 ,3 ]
机构：
[1] Department of Hospital Medicine, Medicine Institute, Cleveland Clinic, Cleveland, OH
[2] Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH
[3] Cleveland, OH 44195, 9500 Euclid Avenue
来源：
Current Heart Failure Reports | 2013年 / 10卷 / 4期
基金：
美国国家卫生研究院;
关键词：
Albuminuria; Anemia; Azotemia; Biomarker; BNP; Creatinine; Cystatin C; e GFR; ESR; Heart failure; Heart failure management; Hyponatremia; Markers; Natriuretic peptide; NGAL; NT-proBNP; Prognosis; Renal insufficiency; Sodium;
D O I：
10.1007/s11897-013-0165-5
中图分类号：
学科分类号：
摘要：
Heart failure is a prevalent and costly disease, and its management with polypharmacy is complex. Commonly available biomarkers primarily help to 1) establish or refute the diagnosis of heart failure; 2) help to determine the disease severity; and 3) identify adverse consequences of treatment. Although several of them are commonly ordered (such as electrolytes, renal and liver function), their use is primarily based on broad clinical experience rather than established evidence. The availability of cardiac-specific natriuretic peptide testing has provided an evidence-based breakthrough in our abilities to establish the diagnosis and severity of heart failure, yet the appropriate boundaries to guide management are still in refinement. © 2013 Springer Science+Business Media New York.
引用
收藏
页码：450 / 457
页数：7
相关论文
共 83 条
[21]  
Francis G.S., Tang W.H., Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions, Prog Cardiovasc Dis, 47, 3, pp. 196-206, (2004)
[22]  
Takashio S., Yamamuro M., Izumiya Y., Et al., Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure, J Am Coll Cardiol, 62, 7, pp. 632-640, (2013)
[23]  
Miller W.L., Hartman K.A., Burritt M.F., Grill D.E., Jaffe A.S., Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure, J Am Coll Cardiol, 54, 18, pp. 1715-1721, (2009)
[24]  
Masson S., Anand I., Favero C., Et al., Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: Data from 2 large randomized clinical trials, Circulation, 125, 2, pp. 280-288, (2012)
[25]  
Blair J.E., Pang P.S., Schrier R.W., Et al., Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial, Eur Heart J, 32, 20, pp. 2563-2572, (2011)
[26]  
Brisco M.A., Coca S.G., Chen J., Et al., Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure, Circ Heart Fail, 6, 2, pp. 233-239, (2013)
[27]  
Testani J.M., Cappola T.P., McCauley B.D., Et al., Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization, Am Heart J, 161, 5, pp. 944-949, (2011)
[28]  
Aghel A., Shrestha K., Mullens W., Borowski A., Tang W.H., Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure, J Card Fail, 16, 1, pp. 49-54, (2010)
[29]  
Damman K., Van Veldhuisen D.J., Navis G., Voors A.A., Hillege H.L., Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure, Eur J Heart Fail, 10, 10, pp. 997-1000, (2008)
[30]  
Maisel A.S., Mueller C., Fitzgerald R., Et al., Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial, Eur J Heart Fail, 13, 8, pp. 846-851, (2011)
123456789